文献速递银屑病与炎症性皮肤病

银屑病患者对局部治疗偏好存在差异:PSO-INSIGHTFUL随机IIIb期研究提示个体化治疗的重要性

Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-09-14

PSO-INSIGHTFUL是一项IIIb期、前瞻性、多中心、开放标签、随机、双臂交叉研究,纳入213例年龄≥18岁的轻至重度银屑病患者,随机1:1先后接受卡泊三醇50μg/g与二丙酸倍他米松0.5mg/g复方泡沫剂和凝胶剂各1周。结果显示50%患者偏好泡沫剂、50%偏好凝胶剂;两种剂型总体可用性评分均高,且常显著优于既往局部治疗;年轻患者(18-39岁)倾向泡沫剂,年长患者(≥40岁)倾向凝胶剂。

要点

  • 银屑病患者对局部治疗剂型偏好多样,泡沫剂与凝胶剂各获50%偏好。
  • 卡泊三醇/倍他米松泡沫剂和凝胶剂总体可用性评分高,常显著优于既往局部治疗。
  • 年龄可能影响剂型偏好:18-39岁倾向泡沫剂,≥40岁倾向凝胶剂。

核心结论

  • 银屑病患者对局部治疗的需求和偏好多样,了解这些偏好有助于为患者选择合适剂型,可能改善依从性和治疗结局。

研究设计与样本

  • PSO-INSIGHTFUL为IIIb期、前瞻性、多中心(加拿大/德国)、开放标签、随机、双臂交叉研究(NCT02310646)。
  • 纳入年龄≥18岁的轻至重度银屑病患者,经过最长4周洗脱期后随机1:1分组。
  • 患者先后接受每日一次卡泊三醇50μg/g与二丙酸倍他米松0.5mg/g复方泡沫剂1周和凝胶剂1周,顺序相反。
  • 共213例患者被随机,其中118例在过去3个月内接受过局部治疗。
  • 患者完成六份评估患者偏好的问卷。

主要发现

  • 基于Subject's Preference Assessment,50%患者偏好卡泊三醇/倍他米松泡沫剂,50%偏好凝胶剂。
  • 基于Topical Product Usability Questionnaire(TPUQ),泡沫剂和凝胶剂总体平均评分均高,且常显著优于既往局部治疗。
  • 当既往治疗为软膏或乳膏时,泡沫剂和凝胶剂与既往局部治疗之间的差异更大。
  • 泡沫剂一般更受年轻患者(18-39岁)偏好,凝胶剂倾向于更受年长患者(≥40岁)偏好。
  • 其他问卷结果与TPUQ一致。

关键数值与推荐

  • 卡泊三醇50μg/g与二丙酸倍他米松0.5mg/g复方泡沫剂和凝胶剂均每日一次,各使用1周。
  • 洗脱期最长4周。
  • 随机比例1:1。
  • 患者年龄≥18岁,银屑病严重程度为轻至重度。

临床怎么用

  • 处方局部治疗时应考虑患者对剂型的个体偏好,而非仅依据疗效。
  • 对年轻患者(18-39岁)可优先考虑泡沫剂,对年长患者(≥40岁)可优先考虑凝胶剂。
  • 若既往使用软膏或乳膏,换用泡沫剂或凝胶剂可能带来更明显的可用性改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poor adherence to topical therapy in psoriasis remains an issue; it is associated with poor clinical outcomes, reduced quality of life and increased costs. Treatment-related factors leading to poor adherence include lack of efficacy, excessive time applying medication and poor cosmetic characteristics (e.g. slow absorption, greasiness). OBJECTIVE: To assess the topical treatment attributes that influence patient preference for fixed combination calcipotriol 50 μg/g (Cal) and betamethasone 0.5 mg/g as dipropionate (BD) foam vs. gel, as well as in comparison with the latest topical treatment (LTT) a patient received. METHODS: PSO-INSIGHTFUL was a Phase IIIb, prospective, multicentre (Canada/Germany), open-label, randomized, two-arm crossover study in patients aged ≥18 years with mild-to-severe psoriasis (NCT02310646). Following a washout period of up to 4 weeks, patients were randomized 1 : 1 to once-daily Cal/BD foam for 1 week, followed by Cal/BD gel for 1 week, or vice versa. Patients completed six questionnaires evaluating patient preferences. RESULTS: A total of 213 patients were randomized; 118 had received a topical treatment in the previous 3 months. Based on the Subject's Preference Assessment, 50% of patients preferred Cal/BD foam and 50% preferred Cal/BD gel. Based on the Topical Product Usability Questionnaire (TPUQ), overall mean scores were high for both Cal/BD foam and gel, and were often significantly in favour of both products compared with LTT. Greater differences between Cal/BD foam and gel vs. LTT occurred when the previous treatment was an ointment or cream. Cal/BD foam was generally preferred by younger patients (aged 18-39 years), whereas Cal/BD gel tended to be preferred by older patients (aged ≥40 years). Results from other questionnaires were aligned with the TPUQ. CONCLUSIONS: Patients with psoriasis have diverse needs and different preferences for topical treatment. This knowledge may help prescribers to choose the right formulation for the right patient, potentially leading to improved adherence and better treatment outcomes.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Hong CH, Papp KA, Lophaven KW, et al. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J Eur Acad Dermatol Venereol. 2017. PMID: 28796913. doi:10.1111/jdv.14515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。